GlassScriptPhysician profile
Nicole Reda
NPI 1306452768
$296.47
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $92.98 · 2022: $203.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $104.63 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.94 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $26.84 | 2022 | |
| Lilly USA, LLC | $26.31 | 2022 | |
| Esperion Therapeutics, INC. | $20.62 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.11 | 2022 | |
| Glaxosmithkline, LLC. | $18.29 | 2021 | |
| Daiichi Sankyo INC. | $13.63 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.10 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Reda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.